Search

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of localised colon cancer was published in 2020. It was decided by both the ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special virtual guidelines meeting in March 2021 to adapt the ESMO 2020 guidelines to take into account the ethnic differences associated with the treatment of localised colon cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with localised colon cancer representing the oncological societies of Japan (JSMO), China (CSCO), India (ISMPO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug availability and reimbursement situations in the different Asian countries., Competing Interests: Disclosure TY has reported research funding from Taiho Pharmaceuticals, Sumitomo Dainippon Pharma Co., Ltd, Chugai Pharmaceutical Co., Ltd, Sanofi KK, Daiichi Sankyo Co., Ltd, Parexel International Inc. and ONO Pharmaceutical Co., Ltd. GA has reported that he has acted as a consultant or speaker for Amgen, Roche, Merck, Sanofi, Servier, Merck Sharp & Dohme and Bayer. EO has declared fees for consultancy, speaking and advisory roles from Eli Lilly, Taiho Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., Takeda, Pharmaceuticals, ONO Pharmaceutical Co., Ltd., Bayer and Bristol-Myers Squibb. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, AstraZeneca, Bayer, Merck Serono, Pierre Fabre, Incyte and Sanofi and speaker support from ESMO. HT declares research funding from RDKK, Sysmex, Daiichi Sankyo, Taiho and Takeda. DA has acted as a consultant or speaker for ACE Oncology, Amgen, Aptitude Health, art tempi media, AstraZeneca, Bayer, Boston Scientific, Bristol-Myers Squibb, CCO, CRA International, Eli Lilly, From Research to Practice, Hexal, Imedex, Ipsen, IQIVIA, Ketchum, MedAhead (Austria), Merck Serono, Merck Sharp and Dohme, Oncolytics, PharmaCept, Pierre Fabre, PRIMA Consulting, Roche, Samsung Bioepsis, Sanofi (Genyme), Terumo and Servier; received fees from Elsevier, WebHealth and Oxford University Press; and institutional funding from Bristol-Myers Squibb, OncoLytics and Pierre Fabre. BKS declares fees for consultancy and advisory roles from Eli Lilly, Novartis, Pfizer, AstraZeneca and Boehringer Ingelheim. IF declares fees for consultancy and advisory roles from Roche, AstraZeneca, Pfizer Merck and Novartis and research funding from Genetech, Samsung and Boehringer Ingelheim. K-HY declares fees for consultancy and advisory roles from Amgen, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, Merck Serono, Eli Lilly, ONO Pharmaceuticals, Takeda, Merck Sharp and Dohme, Daiichi Sankyo and AstraZeneca. GC declares fees for consultancy and advisory roles from AstraZeneca, Daichii Sankyo, Bristol-Myers Squibb, Lilly, Pfizer, Novartis, Ellipsis, Merck and Seagen. HB declares fees for consultancy and advisory roles from Eli Lilly, Taiho Pharmaceuticals and ONO Pharmaceutical Co., Ltd. FL declares fees for consultancy, speaking and advisory roles from Amgen, Astellas, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Eli Lilly, Imedex, MedUpdate, Merck Serono, Merck Sharp and Dohme, Promedicis, Roche, Servier, StreamedUp and Zymeworks; writing fees from Deutscher Arzteverleg, Imedico and Springer-Nature; expert testimony fees from Biontech and Elsevier; and research funding from Bristol-Myers Squibb. TY declares research funding from Chugai, Bayer and Taiho. JT reports personal financial interest in the form of scientific consultancy roles for Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, Merck Sharp and Dohme, Mirati, Neophore, Novartis, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics and TheraMyc; and educational collaborations with Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER). EB declares research funding from Bristol-Myers Squibb, Merck Sharp & Dohme, Eisai, Taiho, Bayer, Eli Lilly and Daichi-Sankyo. AC has reported fees for consultancy and advisory roles from Merck Serono, Amgen, BeiGene and Bristol-Myers Squibb; and research funding from AbbVie, Actuate Therapeutics, Alkermes Inc, Amgen, Astellas Pharma, Beigene, Bioncotech Therapeutics, Boehringer Ingelheim, Debiopharm International, F. Hoffmann-La Roche, FibroGen, Genmab, Janssen Research & Development, MedImmune, Meranini Ricerche, Novartis, Puma Biotechnology, Symphogen, Tahio, Transgene and WNT Research. AO has received research funding from Bristol-Myers Squibb. SP has reported fees for consultancy/advisory roles from AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, Foundation Medicine, Illumina, Imedex, Incyte, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, Roche/Genentech, RTP, Sanofi, Seattle Genetics and Takeda; speaker roles for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Illumina, Imedex, Medscape, Merck Sharp and Dohme, Novartis, PER, Pfizer, Prime, Roche/Genentech, RTP, Sanofi and Takeda; and the receipt of grants/research support: (sub)investigator in trials (institutional financial support for trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, GSK, Illumina, Lilly, Merck Sharp and Dohme, Merck Serono, Mirati, Novartis, Pfizer, Phosplatin Therapeutics and Roche/Genentech. CI has received research funding from Chugai, Taiho, Daiichi-Sankyo, Takeda, Shionogi, Novartis, Eisai, Sanofi, Yakult, Merck Serono, Ono, Kyowa-Kirin, Nippon-Kayaku and Eli Lilly. GP reports fees for consultancy/advisory roles from Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, Merck, Merck Sharp and Dohme and Roche; and institutional funding from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Debiopharm, Enorasis, Genekor, Ipsen, Janssen, Lilly, Merck, Merck Sharp and Dohme, Pfizer, Roche, Sanofi and Servier. The remaining authors have declared no conflicts of interest, (Copyright © 2021. Published by Elsevier Ltd.)

In view of the planned new edition of the most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of primary breast cancer published in 2015, it was decided at the ESMO Asia Meeting in November 2018, by both the ESMO and the Korean Society of Medical Oncology (KSMO), to convene a special face-to-face guidelines meeting in 2019 in Seoul. The aim was to adapt the latest ESMO 2019 guidelines to take into account the ethnic and geographical differences associated with the treatment of early breast cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with early breast cancer representing the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO) Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices, and the drug availability and reimbursement situations, in the individual participating Asian countries., Competing Interests: Disclosure FC has received fees for consultancy/advisory roles from Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Medspace, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Seatlle Genetics and Teva. RD has received fees for consultancy/advisory roles from AstraZeneca, Eisai, Lilly, Merck, Novartis, Pfizer, Roche, and for travel and subsistence from Roche, Merck, Pfizer, Eisai. SG has received research funding from Roche, Sanofi, Johnson & Johnson, Oncostem, Amgen, Celltrion, Novartis, Eisai, Intas and Biocon. S-AI has received fees for consultancy/advisory roles from Amgen, AstraZeneca, Hanmi Corp, Medpacto, Pfizer, Eisai, Novartis, Roche and Lilly, and research funding from AstraZeneca, Pfizer and Roche. HI has received fees for consultancy/advisory roles from Chugai, AstraZeneca, Lilly, Daiich-Sankyo, Pfizer, MSD, Eisai, Kyowa Hakko Kirin, Taiho and Novartis, and research funding from Chugai, AstraZeneca, Lilly, Daiich-Sankyo, Pfizer, MSD, Kyowa Hakko Kirin, Bayer, Novartis and GSK. JHK has received research funding from Ono Pharma Korea Co., Ltd. SCL has received fees for consultancy/advisory roles from Roche, Pfizer, Novartis, Eli Lilly, AstraZeneca and research funding from Taiho, ACT Genomics, Eisai and Pfizer. Y-SL has received fees for consultancy/advisory roles from Pfizer, MSD, Novartis, Boehringer-Ingelheim and Roche, and research funding from MSD, Novartis and Roche. SM has received fees for consultancy/advisory roles from MSD and research funding from ASLAN Pharmaceuticals, MSD, Novartis, Astellas and AstraZeneca. MYM has received research funding from MSD, Mundi Pharma, Astellas, Novartis, AstraZeneca, Sanofi, Roche and Pfizer. YHP has received fees for consultancy/advisory roles from AstraZeneca, Pfizer, Eisai, Novartis, Merck, Roche and Lilly, and research funding from AstraZeneca, Eisai, Merck, Pfizer, Novartis and Roche. GP has received fees for consultancy/advisory roles from Roche, Amgen, MSD, Boehringer and Bristol-Myers Squibb, and research funding from Roche, Amgen, Astellas, Pfizer and Novartis. SS has received fees for consultancy/advisory roles from Novartis, Chugai and Kyowa Kirin, research funding from Chugai, Takeda, Eisai, Taiho and Novartis, and fees for non-CME services received directly from commercial interests or their agents (e.g. speakers bureau) from Pfizer, Novartis, AstraZeneca, Eli Lilly, Eisai, Kyowa Kirin and Chugai, and is an executive board member of the Japan Breast Cancer Society (JBCS) and the Japan Breast Cancer Research Group (JBCRG). ES has received honoraria from Amgen, AstraZeneca, Clinigen, EGIS Pharmaceuticals, Eli Lilly, Genomic Health, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz and TLC Biopharmaceuticals, travel support from Amgen, AstraZeneca, EGIS Pharmaceuticals, Novartis, Pfizer and Roche, and clinical research funding from Amgen, AstraZeneca, Boehringer, Eli Lilly, Merck, Novartis, Pfizer, Roche and Samsung. BKS has received fees for consultancy/advisory roles from Eli Lilly, Dr Reddy's Lab, Cipla and AstraZeneca. TT has received fees for consultancy/advisory roles from AstraZeneca and research funding from Eisai, Chugai, and Novartis Pharma. TY has received research funding from Novartis Pharma K.K., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Sanofi K.K., Daiichi Sankyo Co., Ltd., Parexel International Inc., ONO Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Boehringer Ingleheim Japan, Inc. J-YD, T-YK, KJS, L-MT and YY have declared no conflicts of interest., (Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.)